Nachiket Apte1, Parinita Dherange1, Usman Mustafa1, Lina Ya'qoub1, Desiree Dawson1, Kathleen Higginbotham2, Marjan Boerma3, Daniel P Morin4,5, Dipti Gupta6, Jerry McLarty7, Richard Mansour7, Paari Dominic1. 1. Department of Medicine and Center of Excellence for Cardiovascular Diseases & Sciences, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, United States. 2. Ochsner-LSU Medical Center, Shreveport, LA, United States. 3. Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, United States. 4. Department of Cardiology, Ochsner Medical Center, New Orleans, LA, United States. 5. Department of Cardiology, University of Queensland Ochsner Clinical School, New Orleans, LA, United States. 6. Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States. 7. Department of Medicine and Feist Weiller Cancer Center, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, United States.
Abstract
Background: The association of atrial fibrillation (AF) with cancer and cancer types is inconclusive. Similarly, data regarding the association of AF with different cancer therapies are controversial. Objectives: To study the association of AF with cancer subtypes and cancer therapies. Methods: We studied all patients aged 18-89 years who presented to the Feist Weiller Cancer Center, with or without a diagnosis of cancer, between January 2011 and February 2016. Electronic health records were systematically queried for baseline demographics and ICD-9 and ICD-10 codes for specific co-morbidities. Patients with a diagnosis of AF were tabulated based on cross-validation with the ECG database and/or by recorded history. We assessed the prevalence and risk of AF based on cancer diagnosis, specific cancer type, and cancer therapy. Results: A total of 14,600 patients were analyzed. Compared to non-cancer patients (n = 6,801), cancer patients (n = 7,799) had a significantly higher prevalence of AF (4.3 vs. 3.1%; p < 0.001). However, following correction for covariates in a multivariable logistic regression model, malignancy was not found to be an independent risk factor for AF (p = 0.32). While patients with solid tumors had a numerically higher prevalence of AF than those with hematological malignancies (4.3 vs. 4.1%), tumor type was not independently associated with AF (p = 0.13). AF prevalence was higher in patients receiving chemotherapy (4.1%), radiation therapy (5.1%), or both (6.9%) when compared to patients not receiving any therapy (3.6%, p = 0.01). On multivariable logistic regression, radiation therapy remained an independent risk factor for AF for the entire study population (p = 0.03) as well as for the cancer population (p < 0.01). Conclusions: Radiation therapy for cancer is an independent risk factor for AF. The known association between cancer and AF may be mediated, at least in part, by the effects of radiation therapy.
Background: The association of atrial fibrillation (AF) with cancer and cancer types is inconclusive. Similarly, data regarding the association of AF with different cancer therapies are controversial. Objectives: To study the association of AF with cancer subtypes and cancer therapies. Methods: We studied all patients aged 18-89 years who presented to the Feist Weiller Cancer Center, with or without a diagnosis of cancer, between January 2011 and February 2016. Electronic health records were systematically queried for baseline demographics and ICD-9 and ICD-10 codes for specific co-morbidities. Patients with a diagnosis of AF were tabulated based on cross-validation with the ECG database and/or by recorded history. We assessed the prevalence and risk of AF based on cancer diagnosis, specific cancer type, and cancer therapy. Results: A total of 14,600 patients were analyzed. Compared to non-cancerpatients (n = 6,801), cancerpatients (n = 7,799) had a significantly higher prevalence of AF (4.3 vs. 3.1%; p < 0.001). However, following correction for covariates in a multivariable logistic regression model, malignancy was not found to be an independent risk factor for AF (p = 0.32). While patients with solid tumors had a numerically higher prevalence of AF than those with hematological malignancies (4.3 vs. 4.1%), tumor type was not independently associated with AF (p = 0.13). AF prevalence was higher in patients receiving chemotherapy (4.1%), radiation therapy (5.1%), or both (6.9%) when compared to patients not receiving any therapy (3.6%, p = 0.01). On multivariable logistic regression, radiation therapy remained an independent risk factor for AF for the entire study population (p = 0.03) as well as for the cancer population (p < 0.01). Conclusions: Radiation therapy for cancer is an independent risk factor for AF. The known association between cancer and AF may be mediated, at least in part, by the effects of radiation therapy.
Authors: Hui-Ming Chang; Tochukwu M Okwuosa; Tiziano Scarabelli; Rohit Moudgil; Edward T H Yeh Journal: J Am Coll Cardiol Date: 2017-11-14 Impact factor: 24.094
Authors: M K Chung; D O Martin; D Sprecher; O Wazni; A Kanderian; C A Carnes; J A Bauer; P J Tchou; M J Niebauer; A Natale; D R Van Wagoner Journal: Circulation Date: 2001-12-11 Impact factor: 29.690
Authors: Andrés Enriquez; Jim Biagi; Damian Redfearn; Usama Boles; Dalia Kamel; Fariha Sadiq Ali; Wilma M Hopman; Kevin A Michael; Christopher Simpson; Hoshiar Abdollah; Debra Campbell; Adrian Baranchuk Journal: JACC Clin Electrophysiol Date: 2016-05-18
Authors: Christina Magnussen; Teemu J Niiranen; Francisco M Ojeda; Francesco Gianfagna; Stefan Blankenberg; Inger Njølstad; Erkki Vartiainen; Susana Sans; Gerard Pasterkamp; Maria Hughes; Simona Costanzo; Maria Benedetta Donati; Pekka Jousilahti; Allan Linneberg; Tarja Palosaari; Giovanni de Gaetano; Martin Bobak; Hester M den Ruijter; Ellisiv Mathiesen; Torben Jørgensen; Stefan Söderberg; Kari Kuulasmaa; Tanja Zeller; Licia Iacoviello; Veikko Salomaa; Renate B Schnabel Journal: Circulation Date: 2017-10-16 Impact factor: 29.690
Authors: Nicklas Vinter; Amanda M S Christesen; Morten Fenger-Grøn; Anne Tjønneland; Lars Frost Journal: J Am Heart Assoc Date: 2018-09-04 Impact factor: 5.501